---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041596"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T15:12:44.345541+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics Q2 net loss widens to $4.3M; secures $26.3M line of credit

## Summary
- Q2 2023 revenue $622,807 from licensed molecule sales to Wugen, down sharply from $3.6M in H1 2022; Wugen expected to limit purchases in 2023.
- Net loss $4.3M in Q2 2023 vs $3.5M in Q2 2022; H1 net loss $9.4M vs $5.6M.
- G&A expenses up 76% to $3.0M, driven by legal fees from Altor/NantCell arbitration.
- Secured $26.3M development line of credit with Prime Capital Ventures, maturity April 2028; construction permits for new HQ obtained.
- Cash and equivalents $17.4M as of June 30, 2023; expects to fund operations to Q4 2024.

## SEC filing metadata
- accession: 0000950170-23-041596
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000095017023041596/0000950170-23-041596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000095017023041596/hcwb-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041596
- JSON: https://secwatch.observer/filing/0000950170-23-041596.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041596.txt

## Key facts
- Earnings Releases
  HCW Biologics Inc. reported second quarter ended June 30, 2023 results: revenue $622,807, net income $4.3 million.
  - Period: second quarter ended June 30, 2023
  - Revenue: $622,807
  - Net income: $4.3 million
  - Result: reported results
  source text: gastric cancer, urothelial carcinoma, and melanoma. 2 Second Quarter 2023 Financial Results: • Revenues: Revenues for the quarter ended June 30, 2022 and 2023 were $454,000 and $622,807, respectively. Revenues for the six months ended June 30, 2022 and 2023 were $3.6 million and $664,690, respectively. Revenues were derived exclusively from the sale of licensed
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828673/000095017023041596/0000950170-23-041596-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.